Development, Optimization and Pharmacokinetic Studies of Dasatinib loaded Solid Lipid Nanoparticle and its Therapeutic Efficacy

This research study emphasises the synthesis and evaluation of Dasatinib-loaded solid lipid nanoparticles (SLNs) to enhance the drug's solubility, bioavailability, and therapeutic efficacy. Dasatinib, a tyrosine kinase inhibitor for Chronic Myeloid Leukaemia (CML), exhibits poor water solubility and restricted oral bioavailability, necessitating the advancement of an enhanced drug delivery method. Solid lipid nanoparticles (SLNs) were chosen as a nanocarrier to enhance medication encapsulation, stability, and controlled release, while minimising systemic adverse effects. The findings of this research suggest that Dasatinib-loaded solid lipid nanoparticles (SLNs) are a viable approach to enhance drug solubility, stability, bioavailability, and therapeutic efficacy in the treatment of chronic myeloid leukaemia (CML).